// App-Quantinova.ai

2215 : Pembrolizumab and ipilimumab reduce human RKO colon carcinoma tumor growth in HLA matched CD34-NSG humanized mice

Researchers

Presenter

  • Marcio Lasaro

Principal Investigators

  • Jason M. Davis

  • Mark Ellison

  • Martin R. Graf

  • Vivek Mahajan

  • Aidan Synnott

  • Robert J. Mullin

  • Paula L. Miliani De Marval

Medical Centers

  • Charles River Discovery Research Services, Morrisville, NC.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 4

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Major Histocompatibility Complex, Class I, A

  • Regulatory T cells

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved